Uripan 5 mg 30 tablets

Tradename

Uripan

Composition

Each tablet contains:

oxybutynin hydrochloride 5 mg.

Auxiliary components:

Lactose monohydrate, povidone, hypromelose, magnesium stearate, titanium dioxide, talc.

Properties

M-holinoblokator from the group of tertiary amines. Along with moderate manticholinergic activity, it has the ability to directly influence the smooth muscles of internal organs (myotropic antispasmodic effect). Eliminates spasms and lowers the tone of smooth muscles of internal organs: gastrointestinal tract, biliary tract, uterus, urinary tract, incl. Bladder. With a neurogenic bladder, oxybutynin relaxes the detrusor of the urinary bladder, reduces spontaneous contractions of the detrusor, increases the capacity of the bladder, and reduces the frequency of urge to urinate.

Indications

Urinary incontinence due to instability of the bladder function of a neurogenic nature (hyperreflexia of the detrusor, for example, in multiple sclerosis or spina bifida), or of an idiopathic nature; nocturnal enuresis in children over 5 years of age (as monotherapy or in combination with other drugs).

Method of administration and dosage:

Is taken internally. Adults — 5 mg 1 time / day, after 1 week of treatment, the dose can be increased to 10 mg per day. The maximum daily dose is 20 mg. In elderly patients, at the beginning of treatment, 2.5-3 mg is used 2 times / day, then, if necessary, the dose is gradually increased to 5 mg 2 times / day.

Contraindications

Violation of the outflow of urine from the bladder, when precipitation of retained urine is possible; intestinal obstruction; intestinal atony; severe ulcerative colitis; expansion of the colon; myasthenia gravis; glaucoma; lactation (breastfeeding); children under 5 years old; hypersensitivity to oxybutynin.

Precautions:

Use with caution in elderly patients, with NCD, impaired liver or kidney function, thyrotoxicosis, arrhythmia, coronary artery disease, chronic heart failure, arterial hypertension, initial manifestations of benign prostatic hyperplasia, NUC, in patients with ileostomy, colostomy, and esophageal hernia apertures of the diaphragm, accompanied by reflux esophagitis.

Side effects

From the digestive system: possible dry mouth, nausea, constipation, discomfort in the abdominal region, diarrhea.

From the side of the central nervous system: possible headache, drowsiness, dizziness, decreased visual acuity.

Dermatological reactions: dryness of the skin is possible.